Protara Therapeutics, Inc. (TARA)

NASDAQ: TARA · IEX Real-Time Price · USD
1.40
0.00 (0.00%)
Dec 5, 2023, 4:00 PM EST - Market closed
0.00%
Market Cap 15.91M
Revenue (ttm) n/a
Net Income (ttm) -69.17M
Shares Out 11.36M
EPS (ttm) -6.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,564
Open 1.45
Previous Close 1.40
Day's Range 1.38 - 1.47
52-Week Range 1.04 - 4.18
Beta 1.62
Analysts Strong Buy
Price Target 22.50 (+1,507.14%)
Earnings Date Nov 3, 2023

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jesse Shefferman
Employees 25
Stock Exchange NASDAQ
Ticker Symbol TARA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 1,507.14% from the latest price.

Price Target
$22.5
(1,507.14% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

5 days ago - GlobeNewsWire

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

4 weeks ago - GlobeNewsWire

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

6 weeks ago - GlobeNewsWire

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Dosing is progressing on schedule in ongoing ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24 Dosing is progressing on schedule in ongoing ADVAN...

2 months ago - GlobeNewsWire

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...

3 months ago - GlobeNewsWire

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

4 months ago - GlobeNewsWire

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

7 months ago - GlobeNewsWire

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

7 months ago - GlobeNewsWire

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...

7 months ago - GlobeNewsWire

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

- Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected in 2Q23 –

9 months ago - GlobeNewsWire

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...

9 months ago - GlobeNewsWire

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

10 months ago - GlobeNewsWire

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

11 months ago - GlobeNewsWire

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview

- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

1 year ago - GlobeNewsWire

Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...

1 year ago - GlobeNewsWire

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: KIND
1 year ago - Benzinga

Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

1 year ago - GlobeNewsWire

Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

- Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

1 year ago - GlobeNewsWire

Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way -

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

2 years ago - GlobeNewsWire

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with s...

2 years ago - GlobeNewsWire

Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview

– TARA-002 Confirmatory Large-Scale GMP Comparability Complete –

2 years ago - GlobeNewsWire